Emergent Biosolutions (EBS) to Release Earnings on Wednesday

Emergent Biosolutions (NYSE:EBS) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 6th. Analysts expect Emergent Biosolutions to post earnings of $0.21 per share and revenue of $148.55 million for the quarter. Emergent Biosolutions has set its FY 2025 guidance at EPS.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.49 by $0.22. The business had revenue of $222.20 million during the quarter, compared to the consensus estimate of $218.50 million. Emergent Biosolutions had a negative net margin of 13.63% and a negative return on equity of 0.52%. On average, analysts expect Emergent Biosolutions to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Emergent Biosolutions Price Performance

Emergent Biosolutions stock opened at $5.97 on Tuesday. The stock has a market cap of $323.78 million, a P/E ratio of -2.20 and a beta of 1.97. The company has a fifty day simple moving average of $6.66 and a 200-day simple moving average of $6.71. Emergent Biosolutions has a 12-month low of $4.02 and a 12-month high of $13.28. The company has a current ratio of 6.32, a quick ratio of 3.51 and a debt-to-equity ratio of 1.20.

Insiders Place Their Bets

In other news, Director Keith Katkin sold 7,844 shares of the company’s stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $6.30, for a total value of $49,417.20. Following the completion of the sale, the director directly owned 86,431 shares of the company’s stock, valued at approximately $544,515.30. This represents a 8.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.20% of the stock is currently owned by company insiders.

Institutional Trading of Emergent Biosolutions

A hedge fund recently raised its stake in Emergent Biosolutions stock. Millennium Management LLC grew its holdings in Emergent Biosolutions Inc. (NYSE:EBS) by 68.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,502,488 shares of the biopharmaceutical company’s stock after purchasing an additional 1,020,582 shares during the quarter. Millennium Management LLC owned approximately 4.61% of Emergent Biosolutions worth $12,162,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.